NCT05150691 2026-01-28
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT02157883 2025-11-19
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
AstraZeneca
Phase 1 Completed
NCT02875223 2025-04-20
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
Phase 1 Terminated
NCT05573724 2024-06-18
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT03383692 2023-12-11
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT01772563 2023-09-01
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02706535 2020-11-16
A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
GlaxoSmithKline
Phase 1 Completed
NCT02836171 2017-02-27
Effect of Itraconazole on the Pharmacokinetics of Apatinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT01900028 2016-10-17
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed